Equities

Icecure Medical Ltd

ICCM:NAQ

Icecure Medical Ltd

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.7122
  • Today's Change0.114 / 19.02%
  • Shares traded1.68m
  • 1 Year change-6.29%
  • Beta2.5124
Data delayed at least 15 minutes, as of Nov 22 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.

  • Revenue in USD (TTM)3.34m
  • Net income in USD-13.69m
  • Incorporated2006
  • Employees71.00
  • Location
    Icecure Medical Ltd7 Ha'eshel St.,PO Box 3163CAESAREA 3079504IsraelISR
  • Phone+972 46230333
  • Fax+972 46230222
  • Websitehttps://icecure-medical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Femasys Inc1.26m-18.10m22.46m32.00--3.76--17.81-0.8253-0.82530.05750.26850.08280.33925.2339,395.00-118.95---142.63--65.83---1,436.05--3.26-29.840.4592---11.13---25.04------
Vaso Corp81.65m-118.00k22.62m300.0068.230.882330.190.2770.00190.00190.46490.14621.1125.699.88272,166.70-0.16067.60-0.272816.6259.8658.39-0.14455.821.39--0.0021--2.181.84-57.46---22.33--
Golden Valley Development Inc0.00-92.53k23.94m0.00---------11.17-11.170.00-0.02110.00-------7,710.83-------------3,073.27---3.96--------45.48------
Inspira Technologies Oxy BHN Ltd0.00-11.29m24.89m37.00--3.68-----0.9549-0.95490.000.36660.00----0.00-88.60-114.98-108.36-159.56------------0.00------24.64------
Neuronetics Inc72.71m-36.42m25.32m201.00--2.70--0.3482-1.22-1.222.450.30940.87022.404.57358,182.30-43.59-28.02-54.01-34.7375.7075.73-50.09-51.042.87-3.730.8306--9.426.2218.76--18.57--
Know Labs Inc0.00-16.90m25.94m12.00---------0.1987-0.19870.00-0.020.00----0.00-277.97-212.56-1,477.22-787.19-------2,027.31---11.211.84------17.36---3.66--
Positron Corp1.24m-1.27m28.26m22.00------22.85-0.0897-0.08970.0876-0.11090.59762.296.56---61.35-224.13----32.989.85-102.67-201.870.0638-------10.060.275163.63--4.36--
DarioHealth Corp23.05m-44.23m28.30m249.00--0.4443--1.23-1.29-1.290.64221.870.2132.714.8683,521.74-43.80-73.26-50.02-87.5939.9029.54-205.62-293.541.32--0.3303---26.4122.450.5091--52.42--
IRIDEX Corp48.43m-11.04m28.61m111.00--10.91--0.5908-0.6764-0.67642.960.15771.492.818.03436,315.30-33.90-19.54-56.74-27.4638.8242.67-22.79-15.450.845--0.5125---8.964.02-26.81---24.35--
Icecure Medical Ltd3.34m-13.69m29.63m71.00--2.79--8.88-0.2934-0.29340.07140.21430.17530.843615.0646,985.91-71.93-54.89-92.10-68.6640.3249.87-410.22-313.192.54--0.00--4.6723.5013.70--48.10--
Adagio Medical Holdings Inc0.00-2.54m30.52m----0.7637-----0.1856-0.18560.002.990.00-------6.73---9.12--------------0.1226-------299.85------
Precision Optics Corporation Inc18.98m-3.80m32.32m84.00--3.19--1.70-0.6207-0.62073.111.601.054.214.96225,954.20-20.92-9.07-29.39-13.3828.7233.05-20.01-7.270.7585-15.480.2035---9.2222.93-1,940.92--14.88--
BioSig Technologies Inc39.00k-15.45m33.26m4.00------852.91-1.48-1.480.0033-0.0180.0171--0.8219,750.00-672.27-269.73---363.1164.10---39,405.13-24,485.73---2,513.29-----93.71---6.52---9.58--
Co-Diagnostics Inc7.32m-41.28m33.85m155.00--0.5306--4.62-1.38-1.380.24422.000.08091.2814.8747,232.32-45.605.77-48.526.1549.3082.24-563.9210.946.70--0.000.00-80.09179.54-148.15--101.27--
Vivos Inc23.00k-2.96m36.95m10.00--30.98--1,606.71-0.0076-0.00760.000060.00290.0164--3.54---210.86-202.25-223.27-552.77-29.1310.79-12,884.70-11,969.07----0.00---46.58---17.19------
Data as of Nov 22 2024. Currency figures normalised to Icecure Medical Ltd's reporting currency: US Dollar USD

Institutional shareholders

0.36%Per cent of shares held by top holders
HolderShares% Held
UBS Securities LLCas of 30 Sep 202459.89k0.12%
Virtu Americas LLCas of 30 Jun 202427.19k0.06%
XTX Markets LLCas of 30 Sep 202426.31k0.05%
Geode Capital Management LLCas of 30 Sep 202425.56k0.05%
HRT Financial LP (US)as of 30 Sep 202413.49k0.03%
Concurrent Investment Advisors LLCas of 30 Sep 202410.00k0.02%
Morgan Stanley & Co. LLCas of 30 Sep 20246.07k0.01%
JPMorgan Securities LLC (Investment Management)as of 30 Sep 20245.95k0.01%
Avion Wealth LLCas of 30 Sep 20242.50k0.01%
Bank of America, NA (Private Banking)as of 30 Sep 2024862.000.00%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.